Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (May 2023)
27 slides from Adalta's investor presentation, May 25, 2023
Slide 1: Next generation protein and cell therapies: solutions to debilitating diseases
For personal use only Next generation protein and cell therapies: solutions to debilitating diseases Tim Oldham PhD, CEO and Managing Director, AdAlta (ASX:1AD) Investor presentation, 25 May 2023
Slide 2: Disclaimer
Investor presentation – May 2023 2 Disclaimer For personal use only Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and capi
Slide 3: AdAlta business and focus
Investor presentation – May 2023 3 AdAlta business and focus For personal use only Purpose: going where antibodies cannot to address debilitating diseases Producing a high-value, next generation protein and cell therapy product pipeline for diseases where traditional antibodies are ineffective Disco
Slide 4: AdAlta's portfolio: high value therapeutics and a platform to help other companies
Investor presentation – May 2023 4 AdAlta’s portfolio: high value therapeutics and a platform to help other companies address challenging diseases in fibrosis and immuno-oncology For personal use only Fibrosis: degenerative, progressive, fatal AdAlta’s AD-214 could meet a desperate need for new appr
Slide 5: May 2023 Rights Offer details
Investor presentation – May 2023 5 May 2023 Rights Offer details* For personal use only The Offer Use of funds Allocation of Offer To raise (before exercise of any options) funds (A$ million) approximately A$3.15m Recommence clinical development of 1.36 AD-214 early For every five (5) shares held by
Slide 6: AD-214 program
For personal use only AD-214 program 6
Slide 7: The need: Idiopathic Pulmonary Fibrosis (IPF)
Investor presentation – May 2023 9 The need: Idiopathic Pulmonary Fibrosis (IPF) For personal use only Scarring of the lungs reduces lung function: irreversible, unpredictable, incurable >490,000 people living with IPF2 >40,000 people die every year 3.8 years median survival 88% aged 55 or older Two
Slide 8: AdAlta's solution: AD-214 is being readied for Phase II clinical studies and partnering
Investor presentation – May 2023 8 AdAlta’s solution: AD-214 is being readied for Phase II clinical studies and partnering For personal use only AD-214: strong value proposition built so far Next steps to advance to Phase II First in class molecule targeting validated mode of action Partnering discu
Slide 9: Phase I extension study delivers new data in 2023 to support partnering and Phase II
Investor presentation – May 2023 9 Phase I extension study delivers new data in 2023 to support partnering and Phase II For personal use only AD-214 multidose Phase I extension clinical study • Evaluating safety, PK and PD of multiple 10 mg/kg doses Establishes safety of AD-214 at likely maximum dos
Slide 10: The value: pharma companies license fibrosis assets for significant prices
Investor presentation – May 2023 10 The value: pharma companies license fibrosis assets for significant prices: IPF examples For personal use only Upfront payment Contingent Clinical Phase Date Licensor/target Licensee/acquirer Transaction to licensor milestones at transaction Aug-22 License US$80m
Slide 11: Co-developed immuno-oncology programs: i-CAR-cell therapies
For personal use only Co-developed immuno-oncology programs: i-CAR-cell therapies 11
Slide 12: The need: multifunctional CAR-cell therapies
Investor presentation – May 2023 12 The need: multifunctional CAR-cell therapies For personal use only Therapy involves re-engineering patient’s own immune cells so they “see” cancer as a pathogen – living drug, single dose, potentially curative >US$2.6 billion earned in 20223 US$20.3 billion CAR-T
Slide 13: AdAlta's solution: i-bodies enable superior CAR constructs (i-CARs)
Investor presentation – May 2023 13 AdAlta’s solution: i-bodies enable superior CAR constructs (i-CARs) For personal use only when combined with partner platforms Tiny i-bodies take up LESS room in inserted gene, enabling TWICE the engineered i-body targeting Tumor cell domain functionality Tumor Ch
Slide 14: i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept
Investor presentation – May 2023 14 i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept For personal use only AdAlta i-bodies + Carina cell therapy platform = i-CAR-Ts for solid tumor patients 3 of 5 programs underway; 1 entering proof of concept Significant industry
Slide 15: Co-developed immuno-oncology programs: i-PET imaging
For personal use only Co-developed immuno-oncology programs: i-PET imaging 15
Slide 16: The need: Immuno-oncology (I/O) imaging
Investor presentation – May 2023 16 The need: Immuno-oncology (I/O) imaging For personal use only Immuno-oncology (I/O) drug market is worth US$95 billion1 … … but only 20-40% of patients respond2 to therapy Granzyme B (GZMB) is produced by immune cells to kill cancer: potential biomarker of I/O dru
Slide 17: AdAlta's solution: funded discovery, shorter timeline to royalties for GZMB i-PET
Investor presentation – May 2023 17 AdAlta’s solution: funded discovery, shorter timeline to royalties for GZMB i-PET imaging asset For personal use only AdAlta i-bodies + GE PET technology = GZMB i-PET asset to evaluate the effectiveness of immuno-oncology drugs ü Fully funded discovery program plu
Slide 18: The investment opportunity
For personal use only The investment opportunity 18
Slide 19: AdAlta's pipeline so far: five active assets plus additional partnering opportunities
Investor presentation – May 2023 19 AdAlta’s pipeline so far: five active assets plus additional partnering opportunities For personal use only Discovery Non-clinical Clinical Indication Target Product Partner (route) Lead IND Discovery Preclinical Phase I Phase II optimisation enabling IV Available
Slide 20: Investment proposition
Investor presentation – May 2023 20 Investment proposition For personal use only Fibrosis/inflammation Immuno-oncology i-body platform to create value AD-214: Phase II and partnering in $4.3b 2 co-development collaborations market1 (4 programs) in $20b2 and $6b3 markets Strategy: invest to maintain
Slide 21: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director enquiries@adalta.com.au www.adalta.com.au
Slide 22: Corporate snapshot
Investor presentation – May 2023 22 Corporate snapshot For personal use only Key financial details (28 Apr 2023) Share price performance (ASX:1AD) (last 12 months) HQ and operations Melbourne, Australia Market capitalisation A$8.2m Share price (12 month closing range) A$0.026 ($0.026 - 0.069) 12 mon
Slide 23: Upcoming CY2023 milestones: AD-214 and i-CAR-T data + multiple transaction upside
Investor presentation – May 2023 23 Upcoming CY2023 milestones: AD-214 and i-CAR-T data + multiple transaction upside potential For personal use only Strategy Milestone Impact • HREC approval, 1st participant Phase I extension (Q3 23) Realise Generates new data for partnering, shortens Phase II stud
Slide 24: Experienced, in-house team to execute from discovery through product development
Investor presentation – May 2023 24 Experienced, in-house team to execute from discovery through product development BOARD EXECUTIVE SCIENTIFIC ADVISORY BOARD For personal use only Paul MacLeman Patrick James, PhD Mick Foley, PhD CHAIR DIRECTOR, PLATFORM FOUNDING CHIEF AND PRODUCT SCIENTIST DISCOVER
Slide 25: i-bodies allow for high affinity, high specificity binding to intractable targets
Investor presentation – May 2023 25 i-bodies allow for high affinity, high specificity binding to targets that are intractable for traditional antibodies For personal use only Small Antibodies i-bodies™ Flexible, modular formats Molecules Current pipeline focus CAR cell therapy ADC/ radiotherapeutic
Slide 26: AD-214: efficacy validated in IPF mouse model; safety and target engagement in Phase I
Investor presentation – May 2023 26 AD-214: efficacy validated in IPF mouse model; safety and target engagement in Phase I For personal use only AD-214 inhibited development of lung fibrosis in a mouse AD-214 was well tolerated in Phase I clinical trials and model at a wide range of doses and dose i
Slide 27: i-CAR-T assets: Carina co-development collaboration status
Investor presentation – May 2023 27 i-CAR-T assets: Carina co-development collaboration status For personal use only AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create i-CAR-Ts that could offer improved precision, performance and persistence i-body enabled CAR-T (i-C